January 2017 DMID Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year 2018 Concepts

Fiscal Year 2018 Small Business Innovation Research (SBIR) Contract Solicitation Topics

Partnerships for the Development of Clinically Useful Diagnostics for Antimicrobial-Resistant Bacteria

Request for Applications—proposed FY 2018 initiative

Contact: Maureen Beanan

Objective: The objective of this initiative is to support milestone-driven projects focused on development of clinically informative, diagnostic platforms that identify select antimicrobial-resistant bacterial pathogens and determine associated antimicrobial sensitivity and/or resistance.

Description: NIAID and other agencies/organizations have supported efforts to identify and validate improved pathogen- and host-specific biomarkers of bacterial infectious diseases, particularly those that provide information about associated antimicrobial sensitivities. This initiative will support milestone-driven projects focused on advancing candidate diagnostic platforms that provide phenotypic information about a bacterial pathogen’s drug-susceptibility and/or drug-resistance required to inform a clinician’s therapeutic decisions.

Applications must include data demonstrating proof-of-principle for proposed diagnostic targets and platforms.

Priority will be given to development of diagnostic platforms that detect multiple analytes (e.g., nucleic acids, proteins, lipids) in a single sample, determine antimicrobial sensitivity of targeted pathogens using a rapid (ideally, a maximum of three hours) phenotypic assay, and analyze sample volumes suitable for use in pediatric populations.

In addition, applicants must propose:

  • Development of diagnostic technologies that provide pathogen detection directly from the clinical sample.
  • Development of diagnostic technologies that inform clinicians about antimicrobial sensitivity of targeted bacterial pathogen(s).
  • Substantive investment by at least one industry participant.

Partnerships for the Development of Vaccines and Immunophrophylactics Targeting Multiple Antibiotic-Resistant Bacteria

Request for Applications—proposed FY 2018 initiative

Contact: Michael Schaefer

Objective: To support the development of vaccines and/or immunoprophylactics targeting multiple Gram-negative pathogens that cause nosocomial infections for which therapeutic options are limited or nonexistent.

Description: This initiative will support the development of vaccines and/or immunoprophylactics that target multiple Gram-negative pathogens prevalent in nosocomial infections caused by carbapenem-resistant Klebsiella, multidrug-resistant (MDR) Acinetobacter, and MDR Pseudomonas, beginning with target antigen discovery. Activities to be supported can include identification of novel antigens and demonstration of cross-species protection; completion of proof-of-concept efficacy studies in appropriate models of disease; standard investigational new drug-enabling activities such as GMP manufacturing, stability studies, lot release assays, and execution of good laboratory practices repeated dose toxicology studies; and initial design of a Phase 1 clinical study. The product development effort should be conducted by industry or in close partnership with an industrial collaborator that is most amenable to the Partnerships Program mechanism.

Computational Software Development To Advance Translational Research for Infectious Diseases

Note: NIAID topic for NIH SBIR contract solicitation. 

Request for Proposals

Contact: Charles H. Jackson, Jr.

Improved Diagnostics for Elimination Programs Targeting Malaria and Select Neglected Tropical Diseases (NTDs)

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Induction of Mucosal Immune Response to Parenterally Delivered Vaccines

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Novel Vaccine Technologies and Strategies To Promote Sustained Vaccine Efficacy Against Malaria and Pertussis

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Content last reviewed on February 9, 2017